Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001323 · ClinicalTrials.gov registry record · NA
Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
A NA study, sponsored by Hennepin Healthcare Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT03001323 is a NA study that was terminated before completion, run by Hennepin Healthcare Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT03001323, a NA study, was terminated before completion, sponsored by Hennepin Healthcare Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention group will receive degludec. The investigators will call participants monthly and see them in the clinic every three months.The investigators will follow them for 1 year and evaluate if there will be a difference in rate of DKA in between these two groups.
Interventions
- DRUG Degludec
- DRUG Standard long-acting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-09-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001323
The ClinicalTrials.gov registry entry for NCT03001323 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degludec is the first listed.
NCT03001323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03001323 about?
NCT03001323 is a clinical study titled "Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis". Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA. The investigator will randomize participants to control and intervention group. Control group will receive Lantus/Levemir and intervention ...
What is the current status of trial NCT03001323?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2017-01. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT03001323?
The interventions under investigation include: Degludec (DRUG), Standard long-acting (DRUG).
Who is sponsoring clinical trial NCT03001323?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.